BioMerieux Receivables 2017-2023 | BMXMF

BioMerieux receivables for the quarter ending December 31, 2023 were $1.022B, a 22.13% increase year-over-year.

  • BioMerieux receivables for 2023 were $1.022B, a 4.65% increase from 2022.
  • BioMerieux receivables for 2022 were $0.977B, a 8.47% increase from 2021.
  • BioMerieux receivables for 2021 were $0.9B, a 7.91% increase from 2020.

BioMerieux Receivables 2017-2023 | BMXMF

  • BioMerieux receivables for 2023 were $1.022B, a 4.65% increase from 2022.
  • BioMerieux receivables for 2022 were $0.977B, a 8.47% increase from 2021.
  • BioMerieux receivables for 2021 were $0.9B, a 7.91% increase from 2020.
Related Stocks
Company NameMarket
Cap
Elevance Health (ELV)$114.1B
Cencora (COR)$43.3B
DiDi Global (DIDIY)$24.3B
ICON (ICLR)$24.2B
Avantor (AVTR)$17.2B
Natera (NTRA)$16.1B
Revvity (RVTY)$15.3B
Viatris (VTRS)$13.8B
CochLear (CHEOY)$13.1B
Solventum (SOLV)$11.7B
Medpace Holdings (MEDP)$10.6B
Charles River Laboratories (CRL)$9.8B
Sonic Healthcare (SKHHY)$8.9B
Doximity (DOCS)$8.1B
HealthEquity (HQY)$7.3B
Bausch + Lomb (BLCO)$6.7B
PACS (PACS)$5.9B
Life Times (LTH)$5B
Organon (OGN)$4.7B
Sotera Health (SHC)$4.5B
Surgery Partners (SGRY)$4B
GoodRx Holdings (GDRX)$2.7B
Concentras Parent (CON)$2.7B
Ardent Health Partners (ARDT)$2.6B
BrightSpring Health Services (BTSG)$2.5B
Alignment Healthcare (ALHC)$2.1B
Ryman Healthcare (RYHTY)$2B
Premier (PINC)$1.9B
CareDx (CDNA)$1.6B
Teladoc Health (TDOC)$1.5B